Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2015, Article ID 395826, 9 pages
http://dx.doi.org/10.1155/2015/395826
Review Article

Genetic Consequences of Antiviral Therapy on HIV-1

1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-465 Porto, Portugal
2Centre for Molecular Biology “Severo Ochoa”, Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain

Received 22 February 2015; Revised 26 May 2015; Accepted 27 May 2015

Academic Editor: Qi Dai

Copyright © 2015 Miguel Arenas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. UNAIDS, “2013 report on the global AIDS epidemic,” in Joint United Nations Programme on HIV/AIDS, World Health Organization, 2013. View at Google Scholar
  2. B. S. Peters and K. Conway, “Therapy for HIV: past, present, and future,” Advances in Dental Research, vol. 23, no. 1, pp. 23–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Pérez-Losada, D. Posada, M. Arenas et al., “Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial,” Retrovirology, vol. 6, article 67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. McMichael, L. J. Picker, J. P. Moore, and D. R. Burton, “Another HIV vaccine failure: where to next?” Nature medicine, vol. 19, no. 12, pp. 1576–1577, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. K. S. Slobod, M. Bonsignori, S. A. Brown, X. Zhan, J. Stambas, and J. L. Hurwitz, “HIV vaccines: brief review and discussion of future directions,” Expert Review of Vaccines, vol. 4, no. 3, pp. 305–313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. B. T. Korber, N. L. Letvin, and B. F. Haynes, “T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces,” Journal of Virology, vol. 83, no. 17, pp. 8300–8314, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. D. Siliciano and R. F. Siliciano, “The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure,” Current Opinion in HIV and AIDS, vol. 1, no. 2, pp. 121–128, 2006. View at Google Scholar
  8. L. Menéndez-Arias, “Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments,” Antiviral Research, vol. 98, no. 1, pp. 93–120, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Wensing, V. Calvez, H. F. Gunthard et al., “2014 Update of the drug resistance mutations in HIV-1,” Topics in Antiviral Medicine, vol. 22, no. 3, pp. 642–650, 2014. View at Google Scholar
  10. D. Shriner, A. G. Rodrigo, D. C. Nickle, and J. I. Mullins, “Pervasive genomic recombination of HIV-1 in vivo,” Genetics, vol. 167, no. 4, pp. 1573–1583, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Götte, “The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance,” Current Opinion in Virology, vol. 2, no. 5, pp. 644–650, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Menéndez-Arias, M. A. Martínez, M. E. Quiñones-Mateu, and J. Martinez-Picado, “Fitness variations and their impact on the evolution of antiretroviral drug resistance,” Current Drug Targets: Infectious Disorders, vol. 3, no. 4, pp. 355–371, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. R. van Leeuwen, C. Katlama, R. L. Murphy et al., “A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients,” AIDS, vol. 17, no. 7, pp. 987–999, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Hertogs, S. Bloor, S. D. Kemp et al., “Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples,” AIDS, vol. 14, no. 9, pp. 1203–1210, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. N. M. King, L. Melnick, M. Prabu-Jeyabalan et al., “Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease,” Protein Science, vol. 11, no. 2, pp. 418–429, 2002. View at Google Scholar · View at Scopus
  16. E. Castro-Nallar, M. Pérez-Losada, G. F. Burton, and K. A. Crandall, “The evolution of HIV: inferences using phylogenetics,” Molecular Phylogenetics and Evolution, vol. 62, no. 2, pp. 777–792, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Arenas and D. Posada, “Computational design of centralized HIV-1 genes,” Current HIV Research, vol. 8, no. 8, pp. 613–621, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. N. A. Dona-Rose, G. H. Learn, A. G. Rodrigo et al., “Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope,” Journal of Virology, vol. 79, no. 17, pp. 11214–11224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. D. C. Nickle, M. A. Jensen, G. S. Gottlieb et al., “Consensus and ancestral state HIV vaccines,” Science, vol. 299, no. 5612, pp. 1515–1518, 2003. View at Google Scholar · View at Scopus
  20. A. R. Lemmon and E. C. Moriarty, “The importance of proper model assumption in bayesian phylogenetics,” Systematic Biology, vol. 53, no. 2, pp. 265–277, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. D. C. Nickle, L. Heath, M. A. Jensen, P. B. Gilbert, J. I. Mullins, and S. L. K. Pond, “HIV-specific probabilistic models of protein evolution,” PLoS ONE, vol. 2, no. 6, article e503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Fraser, K. Lythgoe, G. E. Leventhal et al., “Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective,” Science, vol. 343, no. 6177, Article ID 1243727, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. A. F. Y. Poon, S. L. Kosakovsky Pond, D. D. Richman, and S. D. W. Frost, “Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients,” Journal of Virology, vol. 81, no. 24, pp. 13598–13607, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. R. Zolopa, R. W. Shafer, A. Warford et al., “HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed,” Annals of Internal Medicine, vol. 131, no. 11, pp. 813–821, 1999. View at Google Scholar · View at Scopus
  25. J. Durant, P. Clevenbergh, P. Halfon et al., “Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial,” The Lancet, vol. 353, no. 9171, pp. 2195–2199, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Ercoli, L. Sarmati, E. Nicastri et al., “HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity,” AIDS, vol. 11, no. 10, pp. 1211–1217, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Harada, K. Yoshimura, A. Yamaguchi, S. Boonchawalit, K. Yusa, and S. Matsushita, “Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro,” Journal of General Virology, vol. 94, part 5, pp. 933–943, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. R. M. Troyer, K. R. Collins, A. Abraha et al., “Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression,” Journal of Virology, vol. 79, no. 14, pp. 9006–9018, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Arenas, N. Ray, M. Currat, and L. Excoffier, “Consequences of range contractions and range shifts on molecular diversity,” Molecular Biology and Evolution, vol. 29, no. 1, pp. 207–218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Mona, N. Ray, M. Arenas, and L. Excoffier, “Genetic consequences of habitat fragmentation during a range expansion,” Heredity, vol. 112, no. 3, pp. 291–299, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. K. M. Kitrinos, J. A. E. Nelson, W. Resch, and R. Swanstrom, “Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations,” Journal of Virology, vol. 79, no. 16, pp. 10627–10637, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Ibáñez, B. Clotet, and M.-A. Martínez, “Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies,” Journal of General Virology, vol. 81, no. 1, pp. 85–95, 2000. View at Google Scholar · View at Scopus
  33. S. A. Rabi, G. M. Laird, C. M. Durand et al., “Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance,” Journal of Clinical Investigation, vol. 123, no. 9, pp. 3848–3860, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Zhong, Q. Pan, Z. Ning et al., “Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai,” AIDS Research and Human Retroviruses, vol. 23, no. 7, pp. 847–856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. I. Chen, L. Khaki, J. C. Lindsey et al., “Association of pol diversity with antiretroviral treatment outcomes among HIV-infected african children,” PLoS ONE, vol. 8, no. 11, Article ID e81213, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. T. D. Wu, C. A. Schiffer, M. J. Gonzales et al., “Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments,” Journal of Virology, vol. 77, no. 8, pp. 4836–4847, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. R. W. Shafer, R. Kantor, and M. J. Gonzales, “The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors,” AIDS Reviews, vol. 2, no. 4, pp. 211–228, 2000. View at Google Scholar · View at Scopus
  38. D. J. de Sa-Filho, M. D. S. Soares, V. Candido et al., “HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil,” AIDS Research and Human Retroviruses, vol. 24, no. 3, pp. 347–353, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Kantor and D. Katzenstein, “Polymorphism in HIV-1 non-subtype b protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution,” AIDS Reviews, vol. 5, no. 1, pp. 25–35, 2003. View at Google Scholar · View at Scopus
  40. L. B. Arruda, L. A. M. Fonseca, A. J. S. Duarte, and J. Casseb, “Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in São Paulo City, Brazil,” AIDS Research and Human Retroviruses, vol. 26, no. 1, pp. 105–107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. G. S. Gottlieb, R. A. Smith, N. M. Dia Badiane et al., “Hiv-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa,” PLoS ONE, vol. 6, no. 7, Article ID e22204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Garrido, A. M. Geretti, N. Zahonero et al., “Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection,” The Journal of Antimicrobial Chemotherapy, vol. 65, no. 2, pp. 320–326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Piralla, S. Paolucci, R. Gulminetti, G. Comolli, and F. Baldanti, “HIV integrase variability and genetic barrier in antiretroviral nave and experienced patients,” Virology Journal, vol. 8, article 149, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Kulkarni, R. Hluhanich, D. M. McColl, M. D. Miller, and K. L. White, “The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 10, pp. 6145–6150, 2014. View at Publisher · View at Google Scholar
  45. R. Nájera, E. Delgado, L. Pérez-Alvarez, and M. M. Thomson, “Genetic recombination and its role in the development of the HIV-1 pandemic,” AIDS, vol. 16, supplement 4, pp. S3–S16, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Moradigaravand, R. Kouyos, T. Hinkley et al., “Recombination accelerates adaptation on a large-scale empirical fitness landscape in HIV-1,” PLoS Genetics, vol. 10, no. 6, Article ID e1004439, 2014. View at Publisher · View at Google Scholar
  47. M. Pérez-Losada, M. Arenas, J. C. Galán, F. Palero, and F. González-Candelas, “Recombination in viruses: mechanisms, methods of study, and evolutionary consequences,” Infection, Genetics and Evolution, vol. 30, pp. 296–307, 2015. View at Publisher · View at Google Scholar
  48. M. Anisimova, R. Nielsen, and Z. Yang, “Effect of recombination on the accuracy of the likelihood method for detecting positive selection at amino acid sites,” Genetics, vol. 164, no. 3, pp. 1229–1236, 2003. View at Google Scholar · View at Scopus
  49. M. Arenas and D. Posada, “The influence of recombination on the estimation of selection from coding sequence alignments,” in Natural Selection: Methods and Applications, M. A. Fares, Ed., pp. 112–125, CRC Press/Taylor & Francis, Boca Raton, Fla, USA, 2014. View at Google Scholar
  50. M. H. Schierup and J. Hein, “Consequences of recombination on traditional phylogenetic analysis,” Genetics, vol. 156, no. 2, pp. 879–891, 2000. View at Google Scholar · View at Scopus
  51. M. Arenas and D. Posada, “The effect of recombination on the reconstruction of ancestral sequences,” Genetics, vol. 184, no. 4, pp. 1133–1139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M. T. Bretscher, C. L. Althaus, V. Müller, and S. Bonhoeffer, “Recombination in HIV and the evolution of drug resistance: for better or for worse?” BioEssays, vol. 26, no. 2, pp. 180–188, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Pernas, C. Casado, R. Fuentes, M. J. Pérez-Elías, and C. López-Galíndez, “A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection,” Journal of Acquired Immune Deficiency Syndromes, vol. 42, no. 1, pp. 12–18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Fraser, “HIV recombination: what is the impact on antiretroviral therapy?” Journal of the Royal Society Interface, vol. 2, no. 5, pp. 489–503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. N. N. V. Vijay, R. Ajmani, A. S. Perelson, and N. M. Dixit, “Recombination increases human immunodeficiency virus fitness, but not necessarily diversity,” Journal of General Virology, vol. 89, no. 6, pp. 1467–1477, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Shriner, R. Shankarappa, M. A. Jensen et al., “Influence of random genetic drift on human immunodeficiency virus type 1 env evolution during chronic infection,” Genetics, vol. 166, no. 3, pp. 1155–1164, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. L. J. Costa, P. Munerato, R. S. Diaz, and A. Tanuri, “Generation of intersubtype human immunodeficiency virus type 1 recombinants in env gene in vitro: influences in the biological behavior and in the establishment of productive infections,” Virology, vol. 268, no. 2, pp. 440–451, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. M. E. Quiñones-Mateu, Y. Gao, S. C. Ball, A. J. Marozsan, A. Abraha, and E. J. Arts, “In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms,” Journal of Virology, vol. 76, no. 19, pp. 9600–9613, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Posada and K. A. Crandall, “Evaluation of methods for detecting recombination from DNA sequences: computer simulations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13757–13762, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Carvajal-Rodríguez, K. A. Crandall, and D. Posada, “Recombination favors the evolution of drug resistance in HIV-1 during antiretroviral therapy,” Infection, Genetics and Evolution, vol. 7, no. 4, pp. 476–483, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Shi, C. Kitchen, B. Weiser et al., “Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy,” Virology, vol. 404, no. 1, pp. 5–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. C. L. Althaus and S. Bonhoeffer, “Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1,” Journal of Virology, vol. 79, no. 21, pp. 13572–13578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Archer, J. W. Pinney, J. Fan et al., “Identifying the important HIV-1 recombination breakpoints,” PLoS Computational Biology, vol. 4, no. 9, Article ID e1000178, 7 pages, 2008. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  64. M. Nijhuis, C. A. B. Boucher, P. Schipper, T. Leitner, R. Schuurman, and J. Albert, “Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 24, pp. 14441–14446, 1998. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Kim and H. A. Orr, “Adaptation in sexuals vs. asexuals: clonal interference and the Fisher-Muller model,” Genetics, vol. 171, no. 3, pp. 1377–1386, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Foll, Y.-P. Poh, N. Renzette et al., “Influenza virus drug resistance: a time-sampled population genetics perspective,” PLoS Genetics, vol. 10, no. 2, Article ID e1004185, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. A. F. Y. Poon, S. L. Kosakovsky Pond, P. Bennett, D. D. Richman, A. J. Leigh Brown, and S. D. W. Frost, “Adaptation to human populations is revealed by within-host polymorphisms in HIV-1 and hepatitis C virus,” PLoS Pathogens, vol. 3, no. 3, article e45, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Pan, J. Kim, L. Chen, Q. Wang, and C. Lee, “The HIV positive selection mutation database,” Nucleic Acids Research, vol. 35, supplement 1, pp. D371–D375, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Woo, D. L. Robertson, and S. C. Lovell, “Constraints on HIV-1 diversity from protein structure,” Journal of Virology, vol. 84, no. 24, pp. 12995–13003, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. M. John, C. B. Moore, I. R. James, and S. A. Mallal, “Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1,” Antiviral Therapy, vol. 10, no. 4, pp. 551–555, 2005. View at Google Scholar · View at Scopus
  71. N. Beerenwinkel, B. Schmidt, H. Walter et al., “Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 12, pp. 8271–8276, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Arenas, M. C. Villaverde, and F. Sussman, “Prediction and analysis of binding affinities for chemically diverse HIV-1 PR inhibitors by the modified SAFE_p approach,” Journal of Computational Chemistry, vol. 30, no. 8, pp. 1229–1240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. A. M. J. Wensing, N. M. van Maarseveen, and M. Nijhuis, “Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance,” Antiviral Research, vol. 85, no. 1, pp. 59–74, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Y. Rhee, M. J. Gonzales, R. Kantor, B. J. Betts, J. Ravela, and R. W. Shafer, “Human immunodeficiency virus reverse transcriptase and protease sequence database,” Nucleic Acids Research, vol. 31, no. 1, pp. 298–303, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. R. W. Shafer, “Rationale and uses of a public HIV drug-resistance database,” Journal of Infectious Diseases, vol. 194, supplement 1, pp. S51–S58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. S. L. Kosakovsky Pond and S. D. W. Frost, “Not so different after all: a comparison of methods for detecting amino acid sites under selection,” Molecular Biology and Evolution, vol. 22, no. 5, pp. 1208–1222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. R. Batorsky, M. F. Kearney, S. E. Palmer, F. Maldarelli, I. M. Rouzine, and J. M. Coffin, “Estimate of effective recombination rate and average selection coefficient for HIV in chronic infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 14, pp. 5661–5666, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Tamura, G. Stecher, D. Peterson, A. Filipski, and S. Kumar, “MEGA6: Molecular evolutionary genetics analysis version 6.0,” Molecular Biology and Evolution, vol. 30, no. 12, pp. 2725–2729, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Nei, Molecular Evolutionary Genetics, Columbia University Press, New York, NY, USA, 1987.
  80. S. Kullback, “Letter to the editor: the Kullback–Leibler distance,” The American Statistician, vol. 41, no. 4, pp. 340–341, 1987. View at Google Scholar
  81. M. Arenas, H. G. Dos Santos, D. Posada, and U. Bastolla, “Protein evolution along phylogenetic histories under structurally constrained substitution models,” Bioinformatics, vol. 29, no. 23, pp. 3020–3028, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. G. Bello, C. Casado, S. García et al., “Lack of temporal structure in the short term HIV-1 evolution within asymptomatic naïve patients,” Virology, vol. 362, no. 2, pp. 294–303, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. S. L. K. Pond, D. Posada, M. B. Gravenor, C. H. Woelk, and S. D. W. Frost, “Automated phylogenetic detection of recombination using a genetic algorithm,” Molecular Biology and Evolution, vol. 23, no. 10, pp. 1891–1901, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. S. L. Kosakovsky Pond, S. D. W. Frost, and S. V. Muse, “HyPhy: hypothesis testing using phylogenies,” Bioinformatics, vol. 21, no. 5, pp. 676–679, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. D. P. Martin, P. Lemey, M. Lott, V. Moulton, D. Posada, and P. Lefeuvre, “RDP3: a flexible and fast computer program for analyzing recombination,” Bioinformatics, vol. 26, no. 19, Article ID btq467, pp. 2462–2463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Posada, “jModelTest: phylogenetic model averaging,” Molecular Biology and Evolution, vol. 25, no. 7, pp. 1253–1256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Luo, H. Qiao, Y. Zhang et al., “Performance of criteria for selecting evolutionary models in phylogenetics: a comprehensive study based on simulated datasets,” BMC Evolutionary Biology, vol. 10, no. 1, article 242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Guindon, J.-F. Dufayard, V. Lefort, M. Anisimova, W. Hordijk, and O. Gascuel, “New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0,” Systematic Biology, vol. 59, no. 3, pp. 307–321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. T. Hinkley, J. Martins, C. Chappey et al., “A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase,” Nature Genetics, vol. 43, no. 5, pp. 487–490, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. G. J. Henderson, S.-K. Lee, D. M. Irlbeck et al., “Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 2, pp. 623–633, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. D. P. Martin, E. van der Walt, D. Posada, and E. P. Rybicki, “The evolutionary value of recombination is constrained by genome modularity,” PLoS genetics, vol. 1, no. 4, p. e51, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. M. A. Nowak, R. M. Anderson, M. C. Boerlijst, S. Bonhoeffer, R. M. May, and A. J. McMichael, “HIV-1 evolution and disease progression,” Science, vol. 274, no. 5289, pp. 1008–1011, 1996. View at Google Scholar
  93. B. Zöllner, H.-H. Feucht, L. Weitner et al., “Application of HIV-1 genotypic-resistance testing prevents the evolution of further resistance mutations in heavily pretreated patients,” Journal of Clinical Virology, vol. 21, no. 1, pp. 37–45, 2001. View at Publisher · View at Google Scholar · View at Scopus
  94. M. L. Branham, E. A. Ross, and T. Govender, “Predictive models for maximum recommended therapeutic dose of antiretroviral drugs,” Computational and Mathematical Methods in Medicine, vol. 2012, Article ID 469769, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. G. Tirado, G. Jove, R. Kumar et al., “Compartmentalization of drug resistance-associated mutations in a treatment-naive HIV-infected female,” AIDS Research and Human Retroviruses, vol. 20, no. 6, pp. 684–686, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. D. M. Smith, J. K. Wong, G. K. Hightower et al., “Incidence of HIV superinfection following primary infection,” Journal of the American Medical Association, vol. 292, no. 10, pp. 1177–1178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. R. Lorenzo-Redondo, S. Delgado, F. Morán, and C. Lopez-Galindez, “Realistic three dimensional fitness landscapes generated by self organizing maps for the analysis of experimental HIV-1 evolution,” PLoS ONE, vol. 9, no. 2, Article ID e88579, 2014. View at Publisher · View at Google Scholar · View at Scopus